Reported about 1 year ago
In the Taiwan pharmaceutical sales rankings for June 8, 2024, two drugs related to macular degeneration have climbed in the top twenty, including the third-ranked cancer-targeting drug and anti-angiogenic inhibitor 'Avastin,' as well as the six-spot jumping 'Aflibercept.' The prevalence of retinal and choroidal neovascularization as a leading cause of macular degeneration has led to the increased usage of anti-angiogenic inhibitors. With an aging population and expanded insurance coverage, the trend of rising medication use for macular degeneration is expected to continue.
Source: YAHOO